| First Author | Salomaa T | Year | 2022 |
| Journal | J Invest Dermatol | Volume | 142 |
| Issue | 6 | Pages | 1565-1575.e17 |
| PubMed ID | 34808240 | Mgi Jnum | J:326012 |
| Mgi Id | MGI:7294321 | Doi | 10.1016/j.jid.2021.11.013 |
| Citation | Salomaa T, et al. (2022) IL-13Ralpha1 Suppresses Tumor Progression in Two-Stage Skin Carcinogenesis Model by Regulating Regulatory T Cells. J Invest Dermatol 142(6):1565-1575.e17 |
| abstractText | Type 2 inflammationrelated cytokine IL-13 plays a protective role in experimental papilloma induction in mice. To understand the mechanisms by which IL-13 contributes to papilloma formation, we utilized Il13ralpha1-knockout (KO) mice in a widely used 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoyl phorbol-13-acetate two-stage skin carcinogenesis protocol that mimics the development of squamous cell carcinoma. KO mice developed more papillomas and significantly faster than wild-type mice. Papilloma development reduced regulatory T cells in wild-type mice but substantially less in KO mice. In line with this, IL-2 and IL-10 levels decreased in wild-type mice but not in KO mice. Furthermore, systemic IL-5 and TSLP levels were elevated, whereas IL-22 was decreased during papilloma formation in the skin of KO mice. Polymorphonuclear myeloidderived suppressor cells were decreased in the KO mice at the early phase of papilloma induction. We show that IL-13Ralpha1 protects from papilloma development in chemically induced skin carcinogenesis, and our results provide further insights into the protective role of functional IL-4 and IL-13 signaling through type II IL-4 receptor in tumor development. |
